Wall Street Zen Upgrades INmune Bio (NASDAQ:INMB) to “Hold”

INmune Bio (NASDAQ:INMB) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

INmune Bio Stock Performance

NASDAQ INMB opened at $1.29 on Friday. INmune Bio has a one year low of $1.21 and a one year high of $11.64. The company has a market capitalization of $34.29 million, a price-to-earnings ratio of -0.61 and a beta of 0.77. The company’s 50-day simple moving average is $1.55 and its two-hundred day simple moving average is $1.78.

Institutional Investors Weigh In On INmune Bio

A number of large investors have recently made changes to their positions in INMB. Rhumbline Advisers boosted its holdings in shares of INmune Bio by 14.4% in the 1st quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock valued at $150,000 after acquiring an additional 2,409 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in INmune Bio by 20.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock valued at $78,000 after purchasing an additional 8,427 shares during the last quarter. Royal Bank of Canada grew its position in INmune Bio by 44.8% during the 1st quarter. Royal Bank of Canada now owns 29,863 shares of the company’s stock worth $233,000 after purchasing an additional 9,236 shares during the period. Wells Fargo & Company MN grew its position in INmune Bio by 79.0% during the 4th quarter. Wells Fargo & Company MN now owns 24,857 shares of the company’s stock worth $39,000 after purchasing an additional 10,970 shares during the period. Finally, Intech Investment Management LLC purchased a new position in shares of INmune Bio during the 2nd quarter valued at about $26,000. 12.72% of the stock is owned by hedge funds and other institutional investors.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.